Cartesian Therapeutics, Inc.
RNAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $38,913 | $26,004 | $110,777 | $85,077 |
| % Growth | 49.6% | -76.5% | 30.2% | – |
| Cost of Goods Sold | $0 | $0 | $2,037 | $0 |
| Gross Profit | $38,913 | $26,004 | $108,740 | $85,077 |
| % Margin | 100% | 100% | 98.2% | 100% |
| R&D Expenses | $45,105 | $71,260 | $72,377 | $68,736 |
| G&A Expenses | $30,126 | $40,450 | $23,862 | $20,938 |
| SG&A Expenses | $30,126 | $40,450 | $23,862 | $20,938 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $7,579 | $710 | -$2,037 | $0 |
| Operating Expenses | $82,810 | $112,420 | $94,202 | $89,674 |
| Operating Income | -$43,897 | -$86,416 | $14,538 | -$4,597 |
| % Margin | -112.8% | -332.3% | 13.1% | -5.4% |
| Other Income/Exp. Net | -$33,240 | -$152,294 | $20,232 | -$5,124 |
| Pre-Tax Income | -$77,137 | -$238,710 | $34,770 | -$9,721 |
| Tax Expense | $287 | -$19,000 | -$609 | $15,966 |
| Net Income | -$77,424 | -$219,710 | $35,379 | -$25,687 |
| % Margin | -199% | -844.9% | 31.9% | -30.2% |
| EPS | -2.99 | -49.76 | 7.33 | -6.74 |
| % Growth | 94% | -778.9% | 208.8% | – |
| EPS Diluted | -3.29 | -49.76 | 3 | -6.6 |
| Weighted Avg Shares Out | 25,905 | 5,170 | 4,021 | 3,176 |
| Weighted Avg Shares Out Dil | 23,689 | 5,170 | 4,052 | 3,176 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,386 | $4,964 | $0 | $0 |
| Interest Expense | $0 | $2,833 | $3,031 | $2,844 |
| Depreciation & Amortization | $1,151 | $843 | $2,037 | $1,719 |
| EBITDA | -$75,986 | -$235,034 | $39,838 | -$5,158 |
| % Margin | -195.3% | -903.8% | 36% | -6.1% |